Fosmidomycin and multiple analogues of this natural phosphonate product demonstrate promising

antiplasmodial activitiy, but fail to show promising antibacterial activity even when the inhibitory

activity for bacterial and plasmodial DXR is comparable. This projects therefore aims at discovering

new DXR inhibitors with improved bacterial uptake by applying the eNTRy Rules and prodrug

strategies.